ClinicalTrials.gg
RecruitingNCT07214727Updated Nov 18, 2026

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

A Phase 1 interventional study of ALN-5288 and Placebo in Alzheimer's Disease, sponsored by Alnylam Pharmaceuticals. Recruiting at 13 sites in 4 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Alnylam Pharmaceuticals · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 321 studies in Alzheimer Disease with a site in Canada — 60 open to participants now, 81 under way, 23 of them phase 3. Alzheimer Disease · Canada.

Planned enrollment
216th of 281
50 · median 241
Started
2025
with 20 others
Phase 1
10 of 321
2 open now
Primary completion
2030-03
later than 69 of 80 live
Registered
306th of 321
by date

Among the 321 studies in Alzheimer Disease with a site in Canada, this one is the 216th largest by planned enrollment of the 281 interventional ones that give a count, is one of 21 that started in 2025, is one of 10 in phase 1, reaches primary completion later than 69 of the 80 other live ones, and was the 306th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

60 of the 321 studies in Alzheimer Disease with a site in Canada are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 321 studies in Alzheimer Disease with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to:

  • Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD)
  • Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
03

Conditions studied

  • Alzheimer's Disease

Keywords

  • AD
  • Dementia
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is able and willing to meet all study requirements in the opinion of the Investigator
  • Has a diagnosis of Alzheimer's disease (AD) based on clinical findings supported by cerebrospinal fluid (CSF) biomarkers or positive positron emission tomography (PET) amyloid imaging within 7 years prior to screening
  • Has mild cognitive impairment (MCI) or dementia due to AD

Exclusion criteria

Exclusion Criteria:

  • Has non-AD dementia
  • Has (ALT) or aspartate aminotransferase (AST) >2× (ULN)
  • Has total >1.5×ULN
  • Has known infection
  • Has history of virus or current virus infection
  • Has systolic blood pressure >160 mmHg and/or a diastolic blood pressure >100 mmHg after 10 minutes of rest at screening
  • Has an estimated glomerular filtration () of \<45 mL/min/1.73 m\^2 at screening
  • Has abnormalities at screening
  • Has uncontrolled psychiatric disease, including patients deemed by the Investigator to be at significant risk of suicide, major depressive episode, psychosis, confusional state, or violent behavior
  • Has history of bleeding diathesis or coagulopathy due to chronic conditions
  • Has a medical history of brain or spinal disease that would interfere with the IT injection and LP procedures
  • Has history of uncontrolled seizures within the last 6 months prior to Screening
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    ALN-5288

    Participants will be administered ALN-5288 in the Double-blind (DB) Period and Open-Label Extension (OLE) Period.

    Drug: ALN-5288

  • Placebo comparator
    Placebo + ALN-5288

    Participants will be administered placebo in the DB Period and ALN-5288 in the OLE Period.

    Drug: ALN-5288 · Drug: Placebo

Interventions

  • DrugALN-5288

    ALN-5288 will be administered IT.

  • DrugPlacebo

    Placebo will be administered IT.

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events (AEs)

    Time frame: Up to 32 months

  2. Severity of AEs

    Time frame: Up to 32 months

Secondary outcomes

  1. Concentration of Total Tau (t-Tau) Protein in CSF Over Time

    Time frame: Up to 32 months

  2. Change from Baseline in Concentration of t-Tau Protein in CSF Over Time

    Time frame: Up to 32 months

  3. Concentration of ALN-5288 in Plasma Over Time (Ct)

    Time frame: Up to 32 months

  4. Change from Baseline in Concentration of ALN-5288 CSF Ct

    Time frame: Up to 32 months

  5. Concentration of ALN-5288 in Plasma

    Time frame: Up to 32 months

  6. Concentration of ALN-5288 in Urine

    Time frame: Up to 32 months

  7. Concentration of ALN-5288 in CSF

    Time frame: Up to 32 months

07

Study locations

10 of 13 sites recruiting
  • Clinical Trial Site
    Montreal, H3G 1H9, Canada
    Recruiting
  • Clinical Trial Site
    Ottawa, K1Z 1G3, Canada
    Recruiting
  • Clinical Trial Site
    Toronto, M3B 2S7, Canada
    Recruiting
  • Clinical Trial Site
    Toronto, M5T 2S8, Canada
    Not yet recruiting
  • Clinical Trial Site
    's-Hertogenbosch, 5223, Netherlands
    Recruiting
  • Clinical Trial Site
    Amsterdam, 1081 GN, Netherlands
    Recruiting
  • Clinical Trial Site
    Barcelona, 08036, Spain
    Not yet recruiting
  • Clinical Trial Site
    Madrid, 28040, Spain
    Recruiting
  • Clinical Trial Site
    Sant Cugat del Vallès, 08190, Spain
    Not yet recruiting
  • Clinical Trial Site
    Glasgow, G51 4TF, United Kingdom
    Recruiting
  • Clinical Trial Site
    London, WC1N 3BG, United Kingdom
    Recruiting
  • Clinical Trial Site
    Sheffield, S10 2JF, United Kingdom
    Recruiting
  • Clinical Trial Site
    Southampton, SO16 6YD, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2030, 52 months after the start.

Of 162 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 52 months is above that.

Counting every sponsor, half of 235 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2025
First posted
Oct 9, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Mar 6, 2030
CompletionEst.
Mar 6, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
2 updates, last Nov 18, 2026
Show all 2 updates
  1. Nov 18, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Oct 8, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07214727
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Oct 15, 2025
Primary completion
Mar 6, 2030 (estimated)
Completion
Mar 6, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-ALNYLAM
Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-256-9526
Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion